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ABSTRACT 
Objective: To determine if pharmacist-provided medication therapy management (MTM) improves medication adherence in 
Medicare patients.  A secondary objective is to compare the total monthly cost of a patient’s prescription medication regimen 6 
months before and 6 months following a comprehensive medication review (CMR).  Design: Retrospective analysis of medication 
adherence, pre-post comparison.  Setting:  Three independent pharmacies in North Carolina.  Patients: 97 Medicare Part D 
beneficiaries with one or more chronic disease states who participated in a comprehensive medication review (CMR).  Intervention: 
MTM services provided by community pharmacists. Main outcome measure:  Change in adherence as measured by the proportion of 
days covered (PDC) and change in medication costs for patients and third party payers.  Results:  Patients were adherent to chronic 
disease-state medications before and after MTM (PDC≥ 0.8).  Overall, change in mean adherence before and after MTM did not 
change significantly (0.87 and 0.88, respectively; p = 0.43). However, patients taking medications for cholesterol management, GERD, 
thyroid and BPH demonstrated improved adherence following a CMR.  No change in adherence was noted for patients using 
antihypertensives and antidiabetic agents.   Average total chronic disease-state medication costs for participants were reduced from 
$210.74 to $193.63 (p=0.08) following the comprehensive medication review.  Total costs for patient and third party payers 
decreased from patients prescribed antilipemics, antihypertensives, GERD and thyroid disorders following a CMR.  Conclusions:  
Pharmacist-provided MTM services were effective at improving medication adherence for some patients managed with chronic 
medications. Pharmacist-provided MTM services also were effective in decreasing total medication costs.   
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Introduction 
It has been reported that approximately one in four people is 
not adherent to his or her prescribed drug regimen.
1,2   
Nonadherence to long-term medication regimens can lead to 
increased mortality, morbidity and health care costs.
3,4,5   
Reports indicate that 33-69% of medication-related hospital 
admissions in the United States are due to poor medication 
adherence.
6-10  Consequently, lack of adherence has resultant 
financial implications equal to approximately $100 billion 
each year.
10  Nonadherence, particularly in the Medicare 
population, is of concern due to the ubiquity of chronic  
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disease and medication usage.  In a study conducted in 2004 
by Kennedy and colleagues, it was estimated that 
approximately 1.6 million Medicare beneficiaries were not  
filling all of their prescribed medications.
5   Medicare 
beneficiaries with chronic disease states are prescribed 
therapy for optimal disease-state management.  Thus, if 
patients are not adherent by failing to fill or properly take 
prescribed medications, they may experience poor health 
outcomes.    
 
   
The Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of 2003 provided new financial 
opportunities for pharmacists to expand Medication Therapy 
Management (MTM) services and provide comprehensive 
medication reviews (CMR) to all eligible Medicare Part D 
beneficiaries.
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been implemented in pharmacies across the nation to 
improve patient outcomes and aid in the detection of 
medication nonadherence.
7,11,12   MTM, when appropriately 
employed, can lead to improvements in medication 
adherence, recognition in medication therapy problems, and 
reduction in overall health costs.  Research demonstrates 
that a pharmacist may play an integral role in influencing a 
patient’s adherence to a medication regimen.  Project 
ImPACT provided data to suggest that pharmacists working 
collaboratively with patients and health care providers were 
effective in promoting patient adherence with prescribed 
dyslipidemic therapy.
7,11,19  Other studies,  including the 
Asheville Project
13 and the Patient Self-Management Program 
for Diabetes,
14 have demonstrated that pharmacists can 
improve health outcomes and reduce overall health care 
costs.
12   
 
Although a number of studies have evaluated nonadherence 
among Medicare beneficiaries with chronic diseases, limited 
data is available to demonstrate the effectiveness of 
comprehensive medication reviews (CMRs) conducted by 
community pharmacists in the improvement of medication 
adherence.
15, 16  In this study we  investigated if MTM services 
conducted at three independent pharmacies improve 
medication adherence in Medicare patients.  The data 
collected from this research was intended to serve as a 
quality improvement opportunity in MTM service 
performance.   
 
Objectives 
The primary objective of this study was to evaluate if CMRs 
conducted at community pharmacies improve medication 
adherence in Medicare patients.  A secondary objective was 
to compare the total monthly cost of a patient’s prescription 
medication regimen six months before and six months 
following the CMR.   
 
Methods 
Study Design and Setting 
This retrospective, cohort study was initiated at three 
locations of an independent pharmacy in North Carolina. 
These locations are approximately 15 miles apart from one 
another in the towns of Concord, Mount Pleasant and 
Midland, North Carolina.    Moose Pharmacy, a family-owned 
business established in 1882, has been conducting MTM 
services for nearly a decade.  In 2007, Moose Pharmacy’s 
MTM program was greatly enhanced with the development 
of ChecKmeds NC.  ChecKmeds NC, a financially supported 
program developed through the state’s Health and Wellness 
Trust Fund was designed to ensure that Medicare 
beneficiaries were provided a CMR by a pharmacist.  As an 
incentive for pharmacists to provide this service, 
compensation was made available for conducting such face-
to-face medication consultations.  With the opportunity to 
develop quality relationships with our patients and to take 
advantage of financial incentives, Moose Pharmacy began to 
actively provide CMRs for program eligible patients.  
 
Study Participants 
Study participants were drawn from a population of 172 
patients who were receiving known treatment for one or 
more chronic diseases.  Participants included those patients 
who were ≥ 65 years of age, a resident of North Carolina, and 
a Medicare Part D beneficiary.  Patients with a documented 
ChecKmeds NC claim for a CMR during the time period of 
October 2007 through April 2008 were identified using the 
Outcomes Pharmaceutical Health Care® billing platform.  For 
each eligible patient identified to have a CMR during this 
specified time period, prescription refill history was observed 
6 months before and after the documented date of the CMR 
service. Exclusion criteria included patients who refill 
prescriptions at an outside pharmacy and patients who have 
discontinued chronic disease therapy throughout the study 
period.  Patients with disease states that require therapy 
change (i.e. depression and pain management) were also 
excluded.   Each patient who met the inclusion criteria 
underwent evaluation by classification of type of chronic 
disease(s) and treatment regimen(s).  This information was 
acquired by viewing patient medication records stored in 
Visual Pharmacy®, the program utilized in the pharmacies for 
prescription dispensing.    
 
Adherence Analysis 
To determine the extent of each patient’s adherence to a 
chronic disease medication regimen, the proportion of days 
covered (PDC) were calculated 6 months before and 6 
months after CMR documentation for each maintenance 
medication.  PDC is an objective measurement of drug 
adherence that is widely used to evaluate medication 
adherence in chronic diseases and is defined as the number 
of days covered by prescription claims for the same drug or 
for another drug in the same therapeutic class divided by the 
number of days in the specified time interval.
3,20  Patients 
with a PDC ≥ 0.8 were considered adherent.  Conversely, 
patients with a PDC < 0.80 were considered nonadherent.     
After calculating the PDC for each patient’s chronic disease 
medication, change in adherence was analyzed and classified 
either as increased or decreased adherence following the 
CMR.  An average PDC including each patient’s chronic 
medications pre and post- CMR was then configured. 
 
 
Cost Analysis 
The total cost of chronic medications was configured for each 
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analyzed by evaluating each patient’s co-pay per chronic 
medication refill and the third party payment for the chronic 
medications.  The average medication costs for the patient, 
third party payer, and total costs were calculated before and 
after the CMR.   A total average cost of chronic medications 
based on medication classification was also calculated before 
and after the CMR.     
 
Statistical Analysis 
Descriptive statistics were used to report baseline 
characteristics including age, sex, chronic diseases, prescribed 
treatment, and medication costs.  A paired t-test was used to 
analyze adherence before and after CMR of included patients.  
A paired t-test was also used to compare mean medication 
costs before and after the CMR.      
 
Results 
Patient population characteristics 
Of the 172 patients assessed for eligibility, 75 patients were 
excluded from the analysis due to of lack of complete 
pharmacy data.  Discontinuation of therapy, transfer of 
medications to an outside pharmacy and medication 
regimens without chronic medications contributed to these 
exclusions.  A total of 97 patients met the inclusion criteria 
and underwent analysis.  Demographics and baseline 
characteristics of study participants are presented in Table 1.  
The analysis of each patient’s medication regimen involved a 
variety of medication classes including antilipemic, 
antihypertensive, antidiabetic, GERD/heartburn, thyroid, and 
BPH agents (Figure 1).    Medications classified as “Other” 
included asthma and COPD agents, estradiol, conjugated 
estrogens, latanoprost, solifenacin, and pentoxyfylline.   
 
Adherence Analysis 
 As shown in Figure 2, patients were adherent to chronic 
disease-state medications before and after the CMR.  Prior to 
the CMR, patients’ average proportion of days covered was 
0.872.  In the 6 months following the CMR, average 
adherence to chronic medications improved to 0.883.  
Although the mean PDC increased by 1.25%, the difference in 
PDC between the pre-CMR and post-CMR groups [95% CI 
1.17-2.73] was not statistically significant (p=0.43).   Figure 3 
represents average patient adherence before and after the 
CMR based on disease-state.  Patients taking medications for 
cholesterol management GERD, Thyroid and BPH disease-
states demonstrated improved adherence following a CMR 
with an increase mean adherence of 3.5%, 3.4%, 29.4% and 
3.9% respectively.   Patients prescribed antihypertensive and 
antidiabetic medications demonstrated no change in 
adherence following a CMR.    Patients using medications 
classified as “other” demonstrated a 3.9% decrease in 
adherence following the CMR.   
Cost Analysis 
The average dollars spent on the chronic medication regimen 
of study participants is shown in Figure 4.  Six months prior to 
the CMR, patients were paying an average of $45.34 for 
chronic medications.  Six months following the CMR, patient’s 
co-pay increased by $2.45 per regimen on average.  
Conversely, third-party payer cost decreased from pre-CMR 
to post-CMR by $21.55.  Furthermore, total medication costs 
prior to the CMR averaged to be $210.74 as compared to 
$193.63 following the CMR (p=0.08).   
 
The average total dollars spent on chronic medications per 
medication classification is shown in Figure 5.  Following the 
CMR, total costs for patient and third party payers decreased 
for patients taking Antilipemics, Antihypertensives, GERD and 
Thyroid products.  For patients taking medications that fall 
into the “Other” classification and BPH, the total costs for 
patients and third party payers increased by $68.58 and 
$40.38 respectively following the CMR.   
 
Discussion 
This study evaluated whether pharmacist-provided CMRs 
were effective at improving adherence and impacting 
medication costs in our Medicare beneficiaries.  The average 
adherence measure was compared six months before and six 
months after a CMR.  The PDC, an adherence measure, 
increased following the CMR by 1.25%.    
 
When conducting a quality CMR, there are many issues to 
address with a patient regarding his or her medication 
therapy.  Pharmacist-provided MTMs are designed to identify 
drug therapy problems such as: drug interactions, cost-
effective alternatives, adverse drug reactions, unnecessary 
therapy, proper administration/technique, insufficient dose 
and medication underuse.  It is imperative for a pharmacist to 
address underutilization when identified and determine the 
cause of patient non-adherence during complex drug review 
opportunities.   Less than optimal health outcomes can be 
prevented if patient nonadherence is identified and resolved 
by a pharmacist.   
 
There are a variety of ways for pharmacists to provide 
medication adherence interventions.  For example, when 
appropriate, pharmacists should assist in simplifying a 
patient’s drug regimen.
17 Once-daily dosing of medication will 
result in optimal adherence as well as recommending 
combination products when available (i.e. lisinopril/HCTZ).  
Secondly, pharmacists can provide tools to help patients 
remember medication regimens.
8   Encouraging patients to 
use pill boxes, instructing patients to associate pill taking with 
a daily activity, and getting family members involved are 
some examples.  Additional interventions to promote Original Research  PRACTICE BASED RESEARCH 
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medication utilization may include identifying medication 
cost reduction opportunities and clearly communicating 
benefits and risks of medications.  When consulting on a 
particular medication, we educate  patients by highlighting 
the benefits of adherence to regimen, and then discussed the 
risks to help prevent any fear of the medication that may be 
the cause of non adherence.  During a consultation session, it 
is also important to not overwhelm patients when discussing 
a medication side effect profile. Instead, focus education 
strategy on the most commonly reported side effects 
experienced with new therapy.  Patients must feel 
empowered by the education that a pharmacist provides and 
use this knowledge to optimize individualized health 
outcomes.  In many situations, a combination of interventions 
may have the most benefit in improving adherence.
18 
 
A secondary objective was to compare the costs of a patient’s 
medication regimen before and after CMR.  Prescription co-
pays did increase for study participants by $2.45 following the 
CMR.  There are several potential explanations that may be 
offered to explain this increase in patient co-pays and a 
decrease in total medication costs in this project.  One 
possibility is that the pharmacist conducting the CMR may 
have identified a chronic condition that was not properly 
treated.  Thus, the pharmacist addressed this issue by 
recommending an additional medication to the patient’s 
prescriber.  Another explanation is that the pharmacist may 
have recommended a more expensive alternative to current 
medication regimen while recommending that the patient 
discontinue any inappropriate or unnecessary therapy.  
Overall, this scenario would directly affect a patient’s co-pay.  
Finally, the patient may have become more adherent to their 
medication(s).  Based on the results of this study, medication 
adherence did increase.  Therefore, it is not unexpected to 
see a patient’s co-pay increase.    
 
In any scenario, it is important to understand that this cost 
analysis provides only a limited snapshot of total healthcare 
costs and specifically targets prescription medication costs.  
Even though this study demonstrated a slight increase in a 
patient’s copay, total medication costs decreased.  According 
to the results of this study, pharmacist-provided MTM 
services can result in cost saving benefits.  There are many 
advantages in having a prescription drug regimen that is cost-
effective.  One advantage is that, it saves patients with 
Medicare out of pocket costs by avoiding the coverage gap.  
Moreover, generic utilization saves money for third party 
payers.  Currently, a majority of third party payers do not 
recognize pharmacist involvement in cost-savings, and 
therefore do not offer pharmacists financial incentives for 
performing cost saving targeted medication reviews.    
 
Limitations 
This study has several limitations that should be considered.  
First, although some pharmacists at this independent 
pharmacy had experience providing MTM services in the past, 
most pharmacists at this practice site had limited experience 
providing CMRs.  The ChecKmeds program was not fully 
implemented in the pharmacy until October 2007, which was 
the first month of the study period.  Although the CheckMeds 
program greatly enhanced the MTM service at the pharmacy, 
there is a possibility that pharmacists were focusing the CMR 
on issues unrelated to adherence.  Secondly, there was a 
small time frame for adherence and cost assessment (six 
months pre-CMR and six months post-CMR).  Therefore, this 
may not be an adequate time frame to detect a statistical 
significance.  The sample size was also smaller than 
anticipated, thus limiting the sample size and power.  A 
limited sample size may lessen the opportunity to see a 
statistically significant outcome.   The study sites (3 
pharmacies) are all located within 15 miles ofone another.  
Thus, it may be inappropriate to generalize the results for all 
populations as the study cohort was derived from a limited 
area.  Lastly, the study location has been associated with a 
university-related residency program for seven years.  This 
site has also been affiliated with introductory and advanced 
pharmacy practice experience programs with three schools of 
pharmacy.  Therefore, a resident and many students 
completing practice experiences are available to devote 
attention in managing patient medication regimens.  The PDC 
suggested that patients at this pharmacy were adherent six 
months prior to the CMR.  This may be related to increased 
attention to patient’s medication regimen at this study 
location.  Pharmacies that are not associated with schools of 
pharmacy or residency programs may not have additional 
staff to focus on patient’s medication regimens, and would 
therefore be expected to have lower PDCs 6 months prior to 
a CMR.     
 
Conclusions 
Results demonstrated a clinically significant outcome to 
support the effectiveness of MTM services in improving 
medication adherence.  Results failed to demonstrate 
statistically significant evidence to support the effectiveness 
of MTM services in improving medication adherence despite 
improvement in PDC.  MTM, when properly employed may 
be effective in decreasing total medication costs.  This is one 
indication that pharmacist-provided CMRs may be effective at 
decreasing the cost of our patient’s medication regimen.  
Overall, data from this research may enhance pharmacists’ 
MTM delivery skills to recognize when patients are non-
adherent to their medication regimen.  Additional research is 
needed to appropriately evaluate if pharmacist-provided Original Research  PRACTICE BASED RESEARCH 
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MTMs are effective at increasing medication adherence and 
decreasing medication costs.  
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Table 1. Demographics 
N (total)  97 
Gender, No (%) 
Male 
 
33 (34.1) 
Female  64 (65.9) 
Age (years)  75.8 
Number of chronic medications/person, mean (range)  2.22 (1-6) 
 
 
 
 
 
 
 
 
Figure 1: Chronic Medications Used By Participants (n=215) 
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Figure 2: Medication Adherence Before and After Comprehensive Medication Review 
 
 
 
 
 
 
 
Figure 3:  Medication Adherence Before and After Comprehenive Medication Review Per Medication Classification 
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Figure 4: Cost Analysis Before and After Medication Therapy Management 
 
 
 
 
 
 
Figure 5:  Cost Analysis Before and After Medication Therapy Management Per Medication Classification 
 
 
 
 
 